Drug Database
DI

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine (KD370 / KD 370 / Quintovac)

✓ Approved

Meiji Holdings · Vaccine · Vaccine

What is diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine?

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is a vaccine developed by Meiji Holdings. It is approved for therapeutic indications via injectable (others) or intramuscular (im) injection.

Drug Profile

Brand NamesKD370, KD 370, Quintovac
CompanyMeiji Holdings
Drug ClassVaccine
RouteInjectable (Others), Intramuscular (IM) Injection
StatusApproved
Sources: ClinicalTrials.gov, Meiji Holdings

Therapeutic Indications

diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine is developed for 4 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsDiphtheria✓ Approved
Infections and infestationsPertussis✓ Approved
Infections and infestationsTetanus✓ Approved
Surgical and medical proceduresPolio immunisation✓ Approved

Related Research Articles

PubMedCureus2026-08-30

Rare Presentation of Parsonage-Turner Syndrome Post Tdap Vaccination: A Case Report.

Jervis Matthew M, Dunn-Pirio Anastasie A

Parsonage-Turner Syndrome (PTS) is a rare disorder of the brachial plexus typically characterized by acute shoulder and/or upper extremity pain, followed by muscle weakness. Though the specific etiology of PTS is unclear, numerous associations are cited in the literature, including after routine vaccinations. A previously healthy 22-year-old male developed subacute left upper extremity weakness and numbness < 24 hours following a routine Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) booster vaccination, later evolving into diffuse weakness and sharp shoulder pain. Electromyography (EMG) findings were suggestive of early PTS, and subsequent magnetic resonance imaging (MRI) of the brachial plexus confirmed mild inflammatory changes consistent with brachial plexitis. Over several months, the patient showed clinical improvement with conservative management. This case highlights a rare presentation of post-vaccination PTS, emphasizing the need for early recognition and supportive management. Although rare, clinicians should consider PTS in patients presenting with acute-onset upper extremity pain and weakness following vaccination.

PMID 42668845
Read full article →
PubMedExpert review of vaccines2026-08-30

Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad.

Syrkina Olga O, Bausch-Jurken Mary M, Delgado Arlette A, Jovanovic Jelena J et al.

Routine meningococcal vaccination campaigns have substantially reduced the burden of invasive meningococcal disease in pediatric individuals, leading to relative increases in burden in older age groups. There is a need for safe, effective meningococcal vaccines that can be used across broad age ranges. MenACYW-TT, a quadrivalent tetanus-toxoid-conjugate meningococcal vaccine indicated for individuals aged ≥6 weeks, is one such option. This narrative review summarizes safety data from industry-sponsored pre- and post-licensure clinical trials of MenACYW-TT, including head-to-head studies with active comparators and coadministration studies with routine pediatric vaccines. In >30 trials involving >17,000 participants, MenACYW-TT had a consistent safety profile across all age groups, from infants to older adults. The most frequent side effects were generally mild or moderate and transient; vaccine-related serious adverse events were rare (<0.1%). The safety of MenACYW-TT was comparable to that of other quadrivalent meningococcal conjugate vaccines. Coadministration did not materially affect the safety of MenACYW-TT or routine pediatric vaccines. Immunization remains an essential preventive strategy against the potentially life-threatening and life-altering consequences of invasive meningococcal disease. The favorable benefit-risk profile of MenACYW-TT reinforces the safety of licensed vaccines and can help to counter vaccine hesitancy.

PMID 42668391
Read full article →
PubMedZhonghua wai ke za zhi [Chinese journal of surgery]2026-08-30

[Application of JSGPM classification in pancreaticobiliary maljunction].

Weng M Z MZ, Weng H H, Wang Y Y, Wu W J WJ et al.

Objective: To evaluate the clinical value of the Japanese Study Group on Pancreaticobiliary Maljunction(JSGPM) classification in the diagnosis and treatment of pancreaticobiliary maljunction (PBM). Methods: A retrospective cohort analysis was conducted on 103 patients diagnosed with PBM via endoscopic retrograde cholangiopancreatography at the Department of General Surgery, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine from January 2010 to September 2018. There were 32 male cases and 71 female cases; the age (M(IQR)) was 5.1 (39.0) years (range: 2.2 to 56.1 years), with 74 cases aged <12 years and 29 cases aged ≥12 years.The distribution characteristics, clinical manifestations, and treatment strategies of different JSGPM subtypes were compared between pediatric (<12 years) and adolescent/adult (≥12 years) patients. Normally distributed quantitative data were compared between two groups using the independent samples t-test, and among multiple groups using analysis of variance (ANOVA). Skewed quantitative data were compared using non-parametric tests. Categorical variables were compared using the χ² test or Fisher's exact test. Results: Among the 103 PBM patients, JSGPM classified 40 cases as type A (39.2%), 31 cases as type B (30.4%), 25 cases as type C (24.5%), and 6 as type D (5.9%), with no unclassifiable cases. Among patients aged ≥12 years, the incidence of type B PBM was higher than that in children <12 years (51.7% (15/29) vs. 21.6% (16/74); χ²=8.974, P<0.01), and type B was the predominant subtype without concurrent common bile duct dilation (≥12 years vs. <12 years: 12/15 vs. 7/16). Among the 7 pediatric cases (7/16) and 12 adult patients (12/15) with type B PBM without concurrent common bile duct dilation, none underwent extrahepatic bile duct resection; instead, they received only endoscopic sphincterotomy plus cholecystectomy. All patients were followed up for (36±26) months (range: 6 to 96 months), with no recurrence of biliary tract infections, obstructive jaundice, or pancreatitis. Conclusions: The JSGPM classification is concise, practical, and highly correlated with clinical features and prognostic risks, providing clear guidance for individualized diagnosis and treatment. This classification helps identify high-risk type B PBM patients and guides the implementation of precise preventive strategies, avoiding undertreatment or overtreatment.

PMID 42669449
Read full article →
PubMedInternational journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases2026-08-30

Type 2 Diabetes Reshapes the B-Cell Compartment in Tuberculosis, with Reduction of Transitional B Cells and Expansion of Plasmablasts.

Petrone Linda L, Najafi-Fard Saeid S, Altera Anna Maria Gerarda AMG, Aiello Alessandra A et al.

Type 2 diabetes (T2D) increases the risk of tuberculosis (TB) and TB severity; however, its effects on B-cells in the TB-T2D syndemic are not fully understood. We evaluated by flow cytometry, the distribution of circulating B-cell subsets in patients with TB disease, TB-T2D, subjects with TB infection (TBI), TBI-T2D, healthy controls (HCs), T2D, patients with pulmonary respiratory diseases other than TB (ORDs), and ORD-T2D. Plasma levels of unspecific or PPD-specific IgG and B-cell-related soluble factors were measured by multiplex assays. Total B-cell frequency was similar across groups. TB-T2D patients showed decreased transitional B cells compared to TB, TBI-T2D, HC, and T2D. Transitional B-cell frequency significantly and negatively correlated with HbA1c levels in the TB-T2D group. Moreover, plasmablast frequency was increased in TB-T2D compared to TB, TBI-T2D, and T2D. Unspecific or PPD-specific IgG levels were not modulated by T2D. BAFF levels increased in TB and TB-T2D compared to the other groups, whereas the levels of SDF-1 were decreased in TB and TBI irrespective of T2D, compared to the controls. Overall, T2D reshapes B-cell compartments in TB, reducing potentially anti-inflammatory transitional B-cells and increasing plasmablasts, possibly reinforcing inflammation and impacting B-cell development and humoral immunity in TB-T2D.

PMID 42669362
Read full article →
PubMedKidney medicine2026-08-30

COVID-19 Vaccine Knowledge, Practice, and Attitudes Among Hemodialysis Patients in Egypt, Kenya, and Cameroon: A Multicenter Study.

Elsayed Enass E, Kotb Khaled M KM, Heiba Ahmed A, Elhussini Manal Shaker MS et al.

Patients receiving hemodialysis (HD) are at increased risk of severe coronavirus disease 2019 (COVID-19) and were prioritized for vaccination, yet vaccine hesitancy remains common. We assessed COVID-19 vaccine knowledge, acceptance, and attitudes among patients receiving HD in Egypt, Kenya, and Cameroon and identified factors associated with vaccine acceptance, prior infection, willingness to receive future doses, and postvaccination complications. Multicenter cross-sectional survey study. Between March 2021 and April 2022, 765 patients receiving maintenance HD and 196 non-dialysis controls were recruited from dialysis centers in Egypt, Kenya, and Cameroon. Sociodemographic characteristics, clinical comorbidities, prior COVID-19, sources of vaccine information, and exposure to vaccinated or infected relatives. COVID-19 vaccine acceptance, willingness to receive future doses, prior infection, and post-vaccination complications. Structured questionnaires assessed knowledge, practices, and attitudes toward COVID-19 vaccination. Multivariable logistic regression identified factors independently associated with study outcomes. Vaccine acceptance was lower among patients receiving HD than nondialysis controls (58.2% vs 96.2%). Fear of side effects was the most common reason for refusal (39.3%). Postvaccination complications were less frequent among patients receiving HD (22.3% vs 44.3%). Hesitancy was more common among women, younger participants, and those with comorbidities or no prior COVID-19. Having vaccinated or previously infected relatives was associated with a greater willingness to receive future doses. Cross-sectional design limits causal inference. Nonprobability sampling and unmatched controls may limit generalizability. COVID-19 cases may have been underreported because of limited testing. COVID-19 vaccine hesitancy among patients receiving HD is driven by fear, misinformation, and sociodemographic factors. Targeted education and improved access to reliable vaccine information may help increase uptake in this population.

PMID 42668537
Read full article →
PubMedCaspian journal of internal medicine2026-08-30

Bacillus Calmette-Guerin in controlling type 1 diabetes: A quasi-experimental randomized clinical trial.

Ordoei Mahtab M, Behniafard Nasrin N, Namiranian Nasim N, Asadollahi Samira S et al.

T1DM is an autoimmune and chronic metabolic disorder characterized by the destruction of pancreatic beta cells. The Bacillus Calmette--Guérin (BCG) vaccine, originally used for tuberculosis prevention, has shown potential in modulating the immune response and improving beta-cell function. This study aimed to evaluate the therapeutic effects of two doses of BCG vaccine, administered four weeks apart, on glycemic control and selected immunological markers in patients with T1DM. In this single-center, double-blind randomized clinical trial, 33 patients with T1DM were enrolled and randomly assigned to intervention and control groups in a 1:1 ratio, matched by age and sex. The intervention group received two intradermal doses of the BCG vaccine, with a four-week interval. Fasting blood samples were collected at baseline and during follow-up to assess biochemical and immunological parameters. Patients were followed-up for 18 months. IRCT identifier: IRCT20201012049003N1; (date of registration: 2020/10/15). The mean age of participants was 11.25±3.32 years in the control group and 10.69±3.22 years in the BCG group. Anti-ICA levels significantly decreased in the BCG group by the end of the follow-up period. Although there was no significant difference in fasting blood glucose levels between the two groups, a significant reduction in HbA1c was observed in the BCG group after 18 months. The findings suggest that BCG vaccination may contribute to improved long-term glycemic control, as evidenced by reduced HbA1c levels, in patients with T1DM. Additionally, the decrease in Anti-ICA levels indicates a potential immunomodulatory effect, supporting the therapeutic promise of BCG in autoimmune diabetes.

PMID 42669005
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about diphtheria +tetanus + acellular pertussis + polio + haemophilus influnzae type B vaccine